Date: Jun 17, 2014 Source: SoCalTech.com (
click here to go to the source)
Carlsbad-based Isis Pharmaceuticals, which is developing antisense technology for a wide range of conditions, said it has earned $10M in a milestone payment from Biogen Idec today. Isis Pharmaceuticals said the payment is associated with the validation of an undisclosed target to treat a neurological disorder. The two have multiple programs together, where Biogen Idec is tapping Isis PHarmceuticals' antisense technology.
